Curcumin induces caspase and calpain-dependent apoptosis in HT29 human colon cancer cells

NISHA SINGH, ANURAAG SHRIVASTAV and RAJENDRA K. SHARMA

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon S7N 5E5; Saskatchewan Cancer Agency, Saskatoon S7N 4H4, Saskatchewan, Canada

Received October 2, 2008; Accepted January 12, 2009

DOI: 10.3892/mmr_00000148

Abstract. This study aimed to elucidate the mode of action of curcumin (CCM) as an anticancer agent, and to investigate its effects on the proliferation and induction of apoptosis in HT29 human colon cancer cells. We examined the effect of CCM on two cysteine protease families, namely caspases and calpains, which are known to induce apoptosis in a number of cancer cells. We demonstrated that CCM reduces cell proliferation in HT29 cells with an IC50 value of 50±0.015 μM. Western blot analysis indicated that CCM induced apoptosis in HT29 cells by activating the expression of caspases-3 and -12, but not caspase-9. CCM also induced apoptosis in these cells through the involvement of calpain. These findings indicate that CCM-induced apoptosis in HT29 cells follows the caspase-12 apoptotic pathway, and also involves calpain.

Introduction

Colorectal cancer is a major cause of morbidity and mortality in western countries (1). The development of diet-derived chemopreventive agents has recently become a popular area in the field of cancer research. Many diet-derived compounds exhibit promising anticancer properties in epidemiological as well as in experimental studies (2).

Curcumin (CCM) is a naturally occurring polyphenolic compound isolated from the rhizomes of the plant Curcuma domestica. Turmeric has traditionally been recognized in India, China and other Southeast Asian countries as treatment for various diseases (3), and its active compound, diferuloylmethane, is widely used in Indian medicines (4). CCM displays anti-inflammatory, anticancer and antiviral activities (5-7). Several in vitro studies have demonstrated that CCM inhibits the proliferation of cancer cells by cell cycle arrest and induces apoptosis in a variety of cancer cell lines, including HL-60, K562, MCF-7, T98G and HeLa cells (8-10). Furthermore, it has been suggested that CCM suppresses skin, mammary, colon and liver carcinogenesis in a mouse model (11). Although the mechanism of action of CCM as an anticancer agent is not fully understood, the compound is known to activate the mitochondrial-mediated caspase pathway, thus leading to the induction of apoptosis in cancer cells. In Caki cells, CCM deactivated Akt, inhibited Bcl-2, Bcl-XL and IAP, and promoted the mitochondrial release of cytochrome c, activating caspase-3 for apoptosis (12). Similarly, think 937 cells, CCM inhibited Bcl-XL and IAP, but favored cytochrome c release and caspase-3 activation (13). In HL-60 cells, the induction of apoptosis by CCM involved caspase-8-mediated Bid cleavage, cytochrome c release and caspase-3 activation (14). CCM also induced caspase-3-independent apoptosis in Jurrat cells (15) and, in human pancreatic cancer cells, down-regulated NFκB, causing the inhibition of growth and the induction of apoptosis (16).

The anticancer properties of CCM in colon cancer have been demonstrated in vivo and in vitro (17,18). CCM has been shown to inhibit the growth of colon cancer cells by inhibiting cyclooxygenase-2 (COX-2) expression (19). Furthermore, CCM induced apoptosis in HCT116 human colon cancer cells through the JNK signaling pathway (20). Recently, it has been demonstrated that Bax, but not Bak, is a critical regulator of CCM-induced apoptosis (21). Apoptosis can be triggered by two major pathways, the death receptor-associated extrinsic pathway and the mitochondria-dependent intrinsic pathway (22,23). Caspases, a family of cysteine aspartyl-specific proteases, regulate the initiation and the final execution of apoptosis in both pathways (24). Three main pathways are involved in the activation of the caspase cascade: i) the ligand-activated caspase-8 pathway, ii) the mitochondrial pathway, which involves cytochrome c as well as apoptosis-associated caspases-9 and -3, and iii) the endoplasmic reticulum (ER)-specific apoptotic pathway, which involves caspase-12 activation (25). This novel ER-specific apoptotic pathway is activated by caspase-12 (26,27), which in turn may be activated as a result of its proteolytic cleavage by calpain, a non-caspase protease. Calpain, upon activation by elevated intracellular free Ca2+, is known to translocate from the cytosol to the membrane, where it can cleave procaspase-12 to generate active caspase-12 (28). Active caspase-12 is capable of directly activating caspase-3.
In the present study, we attempted to understand the effect of CCM on HT29 cells and investigated the possible underlying mechanisms behind its induction of apoptosis. To this end, CCM-induced apoptosis in HT29 cells was analyzed, and the activation of caspase proteolytic pathways for apoptosis was explored.

Materials and methods

Materials. Curcumin, anti-β-actin antibody, protease inhibitor cocktail for mammalian cell culture, MTT, and other analytical grade reagents were purchased from Sigma (Canada). Anticalpain (m) and calpastatin antibodies were purchased from Chemicon International (Canada). Depending on the primary antibody, the secondary antibodies used were either HRP-conjugated goat anti-mouse or anti-rabbit IgG obtained from Bio-Rad Laboratories (Canada). Anti-caspases-3, -9 and -12, as well as anti-PARP antibodies, were obtained from Cell Signaling Technology (Canada).

Methods

Cell culture and treatment of HT29 cells. The human colon cancer cell line HT29 was obtained from the American Type Culture Collection (ATCC) and grown as monolayers at 37°C in a humidified atmosphere of 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) heat-inactivated fetal calf serum, penicillin (50 U/ml) and streptomycin (50 μg/ml). Cells were grown in a 75-mm tissue culture dish at 37°C containing 10 ml of DMEM. Following trypsinization, the cells were serially passaged using a trypsin/EDTA solution. After 80% confluency was achieved, prior to treatment, the cells were starved for 24 h in DMEM medium. CCM was dissolved in ethyl alcohol to make a stock solution, aliquoted and stored at -20°C. Dose response studies were conducted to determine the IC₅₀ values. HT29 cells were treated with 50 μM CCM for 48 h for the induction of apoptosis.

Western blot analysis. After the treatments, cells were washed with PBS and lysed on ice using 1 ml of lysis buffer containing 50 mM HEPES (pH 7.4), 50 mM sucrose, 20 mM sodium orthovanadate, 50 mM sodium fluoride, 50 μM leupeptin, 1% aprotinin, 2 mM EDTA, 0.1% SDS and 1 mM PMSF. The cells were scraped off the plates and kept on ice for 30 min. Samples were then centrifuged at 13,000 x g for 3 min at 4°C, and the supernatants were stored at -80°C until use. Proteins (20 μg) were resolved by SDS-PAGE and transferred to a PVDF membrane. The membranes were blocked with 5% non-fat dried milk containing 0.02% Tween-20 for 1 h at room temperature, probed with the appropriate antibody, then washed and incubated with the appropriate secondary antibody conjugated to HRP for 1 h at room temperature. After washing, visualization of the polypeptide bands was carried out using a chemiluminescence reagent.

m-Calpain activity. The m-calpain activity in the cell lysate of treated or untreated HT29 cells was determined using Hammerstein grade casein as a substrate (29). Briefly, the assay mixture consisted of 20 mM imidazole-HCl buffer containing 5 mM cysteine (pH 7.5), 5 mg casein, either 5 mM CaCl₂ or 5 mM EGTA, and the cell lysates. The mixture was incubated at 30°C for 30 min.

MTT assay. The MTT assay was carried out to estimate the viability of HT29 cells after incubation with CCM (0-80 μM) following a method described by Mosmann (30). Cells were plated onto a 96-well plate at a density of 1x10⁴ cells/well in 200 μl medium, and were treated with a series of CCM concentrations (0-80 μM) for 24 h. After 24 h, the medium containing CCM was carefully removed, and 50 μl of MTT solution was added to each well. The plate was then read at a wavelength of 540 nm. Cell viability was considered to be 100% at the concentration of 0 μM CCM.

Results

In vitro effect of curcumin on the cell viability of HT29 cells. In order to investigate the cytotoxic properties of CCM, we examined the in vitro effects of different concentrations of CCM on the viability of HT29 cells after 24 h using the MTT assay (Fig. 1). CCM inhibited the growth of HT29 cells in a concentration-dependent manner. At the concentration of 50±0.015 μM, 50% viability was detected during the 24-h treatment, whereas maximum cytotoxicity was observed at a concentration of 80±0.017 μM.

Effect of curcumin on the activity and expression of m-calpain. We used the IC₅₀ concentration of CCM in further studies, with the aim of determining whether calpain is involved in CCM-induced apoptosis in HT29 cells. The m-calpain activity in the cell lysates prepared from CCM-treated or untreated cells was determined using Hammerstein grade casein as a substrate. Increased m-calpain activity was noted in the cell lysate treated with 50 μM CCM (Fig. 2A) as compared to the cells treated with alcohol (positive control) or medium alone (negative control). Furthermore, Western blot analysis revealed the increased expression of m-calpain in the CCM-treated cells (Fig. 2B; lane 3) as compared to the controls (Fig. 2B; lanes 1 and 2).

Effect of curcumin on the expression of caspases-3, -9, -12 and PARP. The results from the MTT assay suggest that...
CCM induces cell death in HT29 cells. To further investigate the mechanism of action of this effect, we examined the expression of the caspases that are the final executioners of apoptosis. Activation of caspase-3 serves as an early marker of apoptosis in a variety of cell types. We therefore first determined whether caspase-3 was activated by CCM in HT29 cells. Cells at 80% confluence were starved and treated with 50 μM CCM for 48 h. Immunoblots of the protein lysates were carried out with anti-caspase-3 antibody (Fig. 3A). To further confirm the activity of caspase-3, the cleavage of its substrate, the nuclear enzyme poly(ADP-ribose) polymerase (PARP), was monitored. The caspase-3-directed proteolysis of the native PARP molecule of molecular mass 116 kDa is detected in immunoblots as an 89-kDa fragment, which acts as a marker of caspase-3 activity (Fig. 3B; lane 3).

Since caspase-3 is activated by the caspase-9-dependent mitochondrial pathway, we examined the expression and activation of caspase-9 by Western blot analysis (Fig. 3C). No increased expression of caspase-9 was noted in the CCM-treated groups, suggesting that this mitochondrial apoptosis pathway was not involved in CCM-induced apoptosis in HT29 cells.

As increased activity of calpain and calpain/caspase-12-mediated apoptosis in other cell types has previously been reported, we also studied the effect of CCM on caspase-12. Expression of caspase-12 was measured by immunoblotting, which revealed an increase in caspase-12 expression after CCM treatment (Fig. 3D; lane 3). This suggests that there was an upregulation in the expression levels of 55-kDa caspase-12 after 48 h of CCM treatment, indicating that caspase-12 plays an important role in CCM-induced apoptosis in HT29 cells.

In vitro effect of curcumin on the expression of calpastatin. The proteolytic activity of calpain is controlled by calpastatin, a known endogenous inhibitor of calpain that may be degraded by calpain and caspsases during apoptosis (31). We examined the effect of CCM on calpastatin levels. Western blot analysis revealed a decrease in the expression of calpastatin in CCM-treated HT29 cells (Fig. 4, lane 3), indicating that CCM diminishes the expression of calpastatin in HT29 cells while increasing the expression and activity of m-calpain (Fig. 2A and B).
Discussion

Plant-derived agents have attracted extensive attention due to their anticancer and antibacterial effects (32,33). The most extensively characterized studies have involved the antitumor effects of these agents, in which several characteristic phenomena of apoptosis were observed, such as cell cycle arrest, DNA damage and the activation of caspases (34,35). In this investigation, we demonstrated that CCM can effectively induce apoptosis via the activation of proteolytic pathways in human colon cancer HT29 cells. CCM is a hydrophobic polyphenolic compound that moves into the cytosol through the plasma membrane (35). This phenolic compound inhibits carcinogenesis, and has been demonstrated to inhibit the proliferation of many human cancer cell lines in vitro.

The present study demonstrated that CCM inhibits the growth of HT29 colon adenocarcinoma cells in a concentration-dependent manner. Maximum cytotoxicity was observed at the highest concentration of 80±0.017 μM (Fig. 1). In concordance with our results, a previous report showed the same type of inhibitory effect after a 72-h treatment (36). Furthermore, CCM has previously been reported to have similar cell growth-inhibiting effects on other colon cancer cell lines (37).

Although previous studies have implicated CCM in the apoptosis of the HT29 cell line, the molecular and cellular mechanisms involved in this process have not been fully elucidated. Exposure to CCM for up to 48 h was found to induce apoptosis in HT29 cells, as evidenced by the activation of caspase-3, a key protease in the execution of apoptosis. There are several routes by which caspase-3 is activated. One is through the release of mitochondrial cytochrome c, the formation of the apoptosome and the activation of caspase-9, which in turn activates the effector caspase-3. Notably, the initiator caspase-9 did not show any activation under similar conditions (Fig. 3C). Our observation of the CCM-mediated activation of caspase-9 leading to apoptosis did not correlate with that of previous studies, conducted on other human colon cancer cells (21,38), squamous cell lung carcinoma and Caki cells (12).

It has previously been reported that a novel Ca2+-mediated calpain/caspase-12-dependent apoptotic pathway exists in breast cancer cells (39). Our findings provide evidence that the CCM treatment of HT29 cells activated the expression of caspase-12 (Fig. 3D), and additionally increased calpain activity (Fig. 2A). Calpain, a neutral Ca2+-dependent cysteine protease, also plays an important role in apoptosis (40). It has been demonstrated that, in apoptotic cells, cooperation between calpain and caspase-3 exists (40). In this study, we also observed that CCM activated the expression of caspase-3 and calpain. Furthermore, expression of calpastatin, an endogenous inhibitor of calpain, was downregulated in the CCM-treated group. These results indicate that CCM induced apoptosis in HT29 cells by means of the caspase/calpain pathway. Increased calpain activity resulted due to the down-regulation of calpastatin. This suggests that activation of the apoptotic pathway by CCM in HT29 cells may have resulted due to the perturbation of calcium homeostasis.

In conclusion, this study provides initial evidence that CCM-mediated apoptosis in the HT29 colon cancer cell line occurs via the calpain/caspase-12 apoptotic pathway.

Acknowledgements

This work was supported by the Canadian Institute of Health Research, Canada. We are thankful to Dr J.R. Dimmock, College of Pharmacy and Nutrition, University of Saskatchewan, for the reading of this manuscript.

References


